2006 ICD-9-CM Volume 1 Diagnosis Codes Home > Neoplasms 140-239 > Malignant Neoplasm Of Lymphatic And Hematopoietic Tissue 200-208 >
  Myeloid leukemia- Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors in the bone marrow and other sites.
- 205 is a non-specific code that cannot be used to specify a diagnosis
  Myeloid leukemia acute- see also M-9930/3
- A type of acute myeloid leukemia, a quickly progressing disease in which too many immature blood-forming cells are found in the blood and bone marrow.
- A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001) -- 2003
- Progressive, malignant disease of the myeloid tissue in which the granular, polymorphonuclear leukocytes and their precursors predominate.
- includes all variants
- A quickly progressing disease in which too many immature blood-forming cells are found in the blood and bone marrow.
- An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the t(15;17)(q22;q12) translocation. There are two variants: the typical and micro granular (hypo granular) variant. This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis. (WHO, 2001) -- 2003
- FAB or WHO type not specified
- 205.0 is a non-specific code that cannot be used to specify a diagnosis
- 205.0 contains 10 index entries
  Myeloid leukemia acute without remission- 205.00 is a specific code that can be used to specify a diagnosis
  Myeloid leukemia acute in remission- Acute myeloid leukemia not growing, responding to treatment
- 205.01 is a specific code that can be used to specify a diagnosis
  Myeloid leukemia chronic- The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis. It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene. Most patients are middle-aged or elderly. Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly. The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase. Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001). -- 2003
- A slowly progressing disease in which too many white blood cells are made in the bone marrow.
- 205.1 is a non-specific code that cannot be used to specify a diagnosis
- 205.1 contains 15 index entries
  Myeloid leukemia chronic without remission- 205.10 is a specific code that can be used to specify a diagnosis
  Myeloid leukemia chronic in remission- Chronic myeloid leukemia not growing; responding to treatment
- 205.11 is a specific code that can be used to specify a diagnosis
  Myeloid leukemia subacute- A myelodysplastic/myeloproliferative disease characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene. The prognosis is usually poor. (WHO, 2001) -- 2003
- 205.2 is a non-specific code that cannot be used to specify a diagnosis
- 205.2 contains 4 index entries
  Myeloid leukemia subacute without remission- 205.20 is a specific code that can be used to specify a diagnosis
  Myeloid leukemia subacute in remission- 205.21 is a specific code that can be used to specify a diagnosis
  Myeloid sarcoma- A tumor mass composed of myeloblasts or immature myeloid cells. It occurs in extramedullary sites or the bone. (WHO, 2001) -- 2003
- An extramedullary tumor of immature myeloid cells. Granulocytic sarcoma usually occurs with or follows the onset of acute myeloid leukemia (LEUKEMIA, MYELOCYTIC, ACUTE).
- see also M-9861/3
- 205.3 is a non-specific code that cannot be used to specify a diagnosis
- 205.3 contains 6 index entries
  Myeloid sarcoma without remission- 205.30 is a specific code that can be used to specify a diagnosis
  Myeloid sarcoma in remission- A myeloid sarcoma that is responding to therapy, i.e. is not progressing and possibly regressing. --2003
- 205.31 is a specific code that can be used to specify a diagnosis
  Other myeloid leukemia- A progressive disease in which the bone marrow is replaced by fibrous tissue and is unable to produce red blood cells; the cause is unknown.
- A chronic myeloproliferative disorder characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. The cause is unknown. The median survival time is 3-5 years from diagnosis. (WHO, 2001) -- 2003
- A disorder in which the bone marrow is replaced by fibrous tissue.
- 205.8 is a non-specific code that cannot be used to specify a diagnosis
- 205.8 contains 8 index entries
  Other myeloid leukemia without remission- 205.80 is a specific code that can be used to specify a diagnosis
  Other myeloid leukemia in remission- 205.81 is a specific code that can be used to specify a diagnosis
  Unspecified myeloid leukemia- Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors in the bone marrow and other sites.
- 205.9 is a non-specific code that cannot be used to specify a diagnosis
- 205.9 contains 6 index entries
  Unspecified myeloid leukemia without remission- 205.90 is a specific code that can be used to specify a diagnosis
  Unspecified myeloid leukemia in remission- Granulocytic leukemia, remission. 1. Abatement or lessening in severity of the symptoms of a disease. 2. The period during which such abatement occurs.
- 205.91 is a specific code that can be used to specify a diagnosis
-
|
|
|